Therefore, interfering with the metabolic addiction of Tfh lymphoma cells from AITL or Tfh PTCL by targeting Bcl-6 might be a therapeutic option since Bcl-6 is important for the survival of both Tfh and GC B cells. The gene discussed is BCL6; the disease is angioimmunoblastic T-cell lymphoma.